Table 3.
TG2 |
Negative Control | ||||
---|---|---|---|---|---|
Cam/ Kan | 15 Amp | 20 Amp | 30 Amp | 15 Amp | |
BIO-1 | + | – | – | – | – |
BIO-2 | + | +++ | +++ | +++ | – |
BIO-3 | + | ++ | + | + | – |
BIO-4 | + | +/– | – | – | – |
BIO-5 | + | +++ | +++ | +++ | – |
SP-1 | + | +++ | +++ | +++ | – |
SP-2 | + | +++ | +++ | +++ | – |
SP-3 | + | +++ | +++ | +++ | – |
SP-4 | + | ++ | + | + | – |
SP-5 | + | +++ | +++ | +++ | –– |
Positive control | + | +++ | +++ | +++ | + |
Negative control | + | – | – | – | – |
In vivo validation of selected interactors. E. coli cells containing the pα-TG2 vector were transformed with the pω vector carrying the cloned interactors. Bacteria were plated on plates supplemented with kanamicin/chloramphenicol to check the presence of both vectors, and on plates supplemented with increasing ampicillin concentration (15 to 20 to 30 μg/ml) and IPTG 1 mM to assay interaction. Positive and negative controls are described in the ‘Materials and Methods’ section.